Evidence map›Paper›PMID 36296600›Full record

ArticleMolecules (Basel, Switzerland)2022

JNC-1043, a Novel Podophyllotoxin Derivative, Exerts Anticancer Drug and Radiosensitizer Effects in Colorectal Cancer Cells.

Jin-Hee Kwon, Na-Gyeong Lee, A-Ram Kang, In-Ho Ahn, In-Young Choi, Jie-Young Song, Sang-Gu Hwang, Hong-Duck Um, Jong-Ryoo Choi, Joon Kim and 1 more

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Therapeutic impacts of GNE‑477‑loaded HInternational journal of molecular medicine · 2024
    Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Jin-Hee KwonDivision of Radiation Biomedical Research, Korea Institute of Radiological and Medical Sciences, Seoul 01812, Korea.
Na-Gyeong LeeDivision of Radiation Biomedical Research, Korea Institute of Radiological and Medical Sciences, Seoul 01812, Korea.
A-Ram KangDivision of Radiation Biomedical Research, Korea Institute of Radiological and Medical Sciences, Seoul 01812, Korea.
In-Ho AhnJ&C Sciences Co., Ltd., KAIST Moonji Campus F712, 193 Moonji-ro, Yusung-Gu, Daejeon 305-732, Korea.
In-Young ChoiJ&C Sciences Co., Ltd., KAIST Moonji Campus F712, 193 Moonji-ro, Yusung-Gu, Daejeon 305-732, Korea.
Jie-Young SongDivision of Radiation Biomedical Research, Korea Institute of Radiological and Medical Sciences, Seoul 01812, Korea.ORCID 0000-0002-5769-3886
Sang-Gu HwangDivision of Radiation Biomedical Research, Korea Institute of Radiological and Medical Sciences, Seoul 01812, Korea.
Hong-Duck UmDivision of Radiation Biomedical Research, Korea Institute of Radiological and Medical Sciences, Seoul 01812, Korea.
Jong-Ryoo ChoiJ&C Sciences Co., Ltd., KAIST Moonji Campus F712, 193 Moonji-ro, Yusung-Gu, Daejeon 305-732, Korea.
Joon KimDivision of Life Sciences, Korea University, Seoul 02841, Korea.
Jong Kuk ParkDivision of Radiation Biomedical Research, Korea Institute of Radiological and Medical Sciences, Seoul 01812, Korea.
Korea Institute of Radiological and Medical Sciences · KRKorea Advanced Institute of Science and Technology · KRKorea University · KR

Funding

Ministry of Science ICT and Future Planning 505312022Ministry of Science ICT and Future Planning 505382022National Research Foundation of Korea 2021R1F1A1055981National Research Foundation of Korea NRF-2020M2D9A2094153
6 · The paper itself

Abstract

The objective of this study was to determine whether (5S)-5-(4-benzyloxy-3,5-dimethoxy-phenyl)-5,9-dihydro-8H-furo [3',4':6,7] naphtho [2,3-d] [1,3]dioxol-6-one (JNC-1043), which is a novel chemical derivative of β-apopicropodophyllin, acts as a novel potential anticancer reagent and radiosensitizer in colorectal cancer (CRC) cells. Firstly, we used MTT assays to assess whether JNC-1043 could inhibit the cell proliferation of HCT116 and DLD-1 cells. The IC50 values of these cell lines were calculated as 114.5 and 157 nM, respectively, at 72 h of treatment. Using doses approximating the IC50 values, we tested whether JNC-1043 had a radiosensitizing effect in the CRC cell lines. Clonogenic assays revealed that the dose-enhancement ratios (DER) of HCT116 and DLD-1 cells were 1.53 and 1.25, respectively. Cell-counting assays showed that the combination of JNC-1043 and γ-ionizing radiation (IR) enhanced cell death. Treatment with JNC-1043 or IR alone induced cell death by 50~60%, whereas the combination of JNC-1043 and IR increased this cell death by more than 20~30%. Annexin V-propidium iodide assays showed that the combination of JNC-1043 and IR increased apoptosis by more 30~40% compared to that induced by JNC-1043 or IR alone. DCFDA- and MitoSOX-based assays revealed that mitochondrial ROS production was enhanced by the combination of JNC-1043 and IR. Finally, we found that suppression of ROS by N-acetylcysteine (NAC) blocked the apoptotic cell death induced by the combination of JNC-1043 and IR. The xenograft model also indicated that the combination of JNC-1043 and IR increased apoptotic cell death in tumor mass. These results collectively suggest that JNC-1043 acts as a radiosensitizer and exerts anticancer effects against CRC cells by promoting apoptosis mediated by mitochondrial ROS.

Indexed as

Antineoplastic AgentsColorectal NeoplasmsRadiation-Sensitizing AgentsAcetylcysteineAnnexin A5ApoptosisCell Line, TumorCell ProliferationHumansPodophyllotoxinPropidiumReactive Oxygen SpeciesAcetylcysteineAnnexin A5Antineoplastic AgentsPodophyllotoxinPropidiumRadiation-Sensitizing AgentsReactive Oxygen Speciesapoptosiscolorectal cancerJNC-1043radiosensitizerROStopoisomerase inhibitor

Identifiers

PMID36296600
PMCPMC9607161
OpenAlexW4306766795

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.